
XOMA (XOMA) Stock Forecast & Price Target
XOMA (XOMA) Analyst Ratings
Bulls say
XOMA Royalty Corp is poised for substantial revenue growth, with an anticipated annual increase of over 20% through 2026, driven by commercial sales of products like Vabysmo and recent launches such as Ojemda and Miplyffa. The Company's total income from royalty agreements surged to $28.5 million in 2024, a significant rise from $4.8 million in 2023, underscoring the effectiveness of XOMA's strategy in acquiring future economic rights and expanding its royalty aggregate. Projections for 2026 suggest revenues may reach $49.0 million, representing a 36% increase from 2025, further enhanced by potential contributions from earlier-stage assets and milestone payments, indicating a robust growth trajectory for XOMA.
Bears say
XOMA Royalty Corp has experienced revenue and net earnings variability, which stems from the fluctuations in the international market for its products; this susceptibility to global economic downturns, new tariffs, and changes in governmental reimbursement policies poses a risk to its operations. The company's reliance on the outcomes of clinical trials and its ability to secure funding for drug development further heighten the uncertainty, especially following the recent removal of a near-term revenue driver from its financial projections. Additionally, the potential departure of key executives could severely impact XOMA's operational knowledge and industry expertise, contributing to a bleak outlook for the company's stock performance.
This aggregate rating is based on analysts' research of XOMA and is not a guaranteed prediction by Public.com or investment advice.
XOMA (XOMA) Analyst Forecast & Price Prediction
Start investing in XOMA (XOMA)
Order type
Buy in
Order amount
Est. shares
0 shares